Personalizing
Cancer Treatment for Everyone

PUBLISHED RESEARCH
Considerations and Advancements of Precision Medicine in GI Cancers
Considerations and Advancements of Precision Medicine in GI Cancers

This activity is designed to inform physicians about the current availability and use of targeted therapies and precision medicine in gastric (GC) and other gastrointestinal (GI) cancers.

 

412
Oral Versus IV Oncolytics

Here, we have oral drugs. How do these oral oncolytics compare to the parenteral drugs–the only drugs, really, when I was growing up in medicine–in terms of use and in terms of access?

 

414
Follicular Lymphoma Regimens Equivalent

Two widely used regimens for advanced-stage follicular lymphoma led to similar high rates of long-term survival, as reported in the Journal of Clinical Oncology.

 

415
Extended AI Can Stop after 2 Years

Continuing adjuvant aromatase inhibitor (AI) therapy for 2 years beyond the current standard 5 years of treatment yielded the same level of recurrence prevention as continuing the treatment for an extra 5 years, according to a report at the San Antonio Breast Cancer Symposium.

 

413
FDA Approves NGS Test for Multiple Mutations

The FDA approved a next-generation sequencing test that can detect multiple mutations in any solid tumor.

 

365
Radical Treatment of the Primary Tumor in Metastatic Bladder Cancer: Potentially Dangerous Findings From Observational Data

Population-based observational studies allow investigators to evaluate the adoption of new therapies and to determine whether benefits seen in clinical trials are realized in the real world.

 

341
Clinical outcome of patients with metastatic renal cell carcinoma who interrupted VEGFR-TKI after achieving stable disease or better response.

The purpose of the this study is to evaluate the clinical outcome of VEGFR-TKIs interruption in patients with metastatic renal cell carcinoma (mRCC) after achieving stable disease (SD) or better response.

330
Tumor Heterogeneity Predicts Metastatic Potential in Colorectal Cancer

Tumors continuously evolve to maintain growth; secondary mutations facilitate this process, resulting in high tumor heterogeneity. In this study, we compared mutations in paired primary and metastatic colorectal cancer tumor samples to determine whether tumor heterogeneity can predict tumor metastasis.

284
Overall Survival Rate Increased in Gastric Cancer

Docetaxel-based chemotherapy led to significant improvement in progression-free (PFS) and overall survival for patients with resectable gastric or gastroesophageal juncture (GEJ) cancer, according to a study reported at the European Society for Medical Oncology conference in Madrid.

285
Liposuction Reduces Swelling and Pain Associated with Lymphedema

Liposuction for primary or secondary lymphedema led to substantial reductions in limb swelling and associated pain, according to a case report in the New England Journal of Medicine.

286
PARP Inhibitor Active in Non-BRCA Breast Tumors

A PARP inhibitor demonstrated activity in triple-negative breast cancer (TNBC) xenografts without BRCA1/2 mutations, investigators reported online in Clinical Cancer Research.

Stay in Touch with Us
To speak with a dedicated cancer care specialist, contact us by one of the options listed below:
PLEASE FILL OUT FORM BELOW

X
Talk to Cancer Care Experts:
+1 (844) 627-7246
Top